This work supports the goal of dual-purpose clinical trial designs that integrate aging endpoints into studies for specific disease indications by identifying potential anti-aging shifts in senescence and metabolic processes alongside the anti-fibrotic activity of rentosertib.
Abstract
Drugs for aging-related diseases may modulate aging itself, but standard clinical trial designs cannot detect such effects. Aging clocks could close this gap, but epigenetic models often yield inconsistent, hard-to-interpret results. In contrast, proteomic clocks, by tracking the immediate effectors of biological change, may excel in providing aging biomarkers or mechanistic insight. Here we compare six proteomic clocks (ProtAge, OrganAgemortality, OrganAgechrono, PAC, ipfP3GPT and PAOPAC) on serum proteomes from a published 12-week phase 2a trial of the candidate anti-fibrotic drug rentosertib in idiopathic pulmonary fibrosis. We measure the variance between the clocks and find that all six clocks consistently predicted lower biological age in treated arms. However, proteomic clocks alone cannot deconvolute aging- and disease-specific effects. We addressed this issue indirectly through pathway analyses that identified potential anti-aging shifts in senescence and metabolic processes alongside the anti-fibrotic activity of rentosertib. This work supports the goal of dual-purpose clinical trial designs that integrate aging endpoints into studies for specific disease indications.
Biological age (BA) has been proposed as a complementary construct to chronological age (CA) for quantifying interindividual heterogeneity in aging trajectories. Biological aging clocks (BACs) integrate molecular, clinical and multi-omics biomarkers to estimate aging-related phenotypes beyond CA. This narrative review...
C. Fermín-Martínez, S. Garcia-Gonzalez, Elizabeth Garcia L. Castañeda et al.· Revista de investigacion cli...· 0 citations
The potential of plasma proteomic clocks in detecting AD‐related phenotypes and co‐morbidities possibly constitute confounding factors, compromising the performance of proteomic aging models is illustrated.
Cindy David Sarmento, G. Drouard, T. Saari et al.· Alzheimer's & Dementia· 1 citation
This review synthesizes current evidence on proteomic biomarkers across major physiological systems, including the immune, metabolic/endocrine, cardiovascular, musculoskeletal, and nervous systems, and highlights shared molecular signatures that underpin multisystem decline.
Ying Luo, Yu-Lin Xiao, Jie-Hua Chen et al.· Frontiers in Aging· 0 citations
Aging biomarkers can potentially allow researchers to rapidly monitor the impact of an aging intervention without the need for decade-spanning trials. However, before the use of aging biomarkers, such as epigenetic clocks, as surrogate endpoints, their responsiveness to interventions that target aging must be tested. H...
R. Sehgal, Daniel S. Borrus, J. Armstrong et al.· Nature Medicine· 2 citations